![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MA McAuley and TC Westfall
Department of Pharmacological and Physiological Science, Saint Louis University Medical Center, Missouri.
Earlier investigation of the vascular actions of Neuropeptide Y (NPY) led us to propose that distinct receptors mediated the prejunctional inhibition of periarterial nerve-stimulated norepinephrine (NE) release and the postjunctional potentiation of the increase in perfusion pressure elicited by vasoconstrictors. These receptors were designated Y2 and Y1, respectively, based on the ability of C-terminal fragments to mimic the former action. The present study investigates further the involvement of these putative receptor subtypes in the isolated and perfused mesenteric arterial bed. [Leu31Pro34]NPY, a novel analog with specificity at the Y1 receptors, potentiated the increase in perfusion pressure elicited by exogenously administered NE and arginine vasopressin, confirming the existence of this NPY subtype postjunctionally. This immediate and prolonged potentiation was abolished by phentolamine, attenuated by benextramine and the reputed NPY antagonist, PYX1. [11-36]NPY also produced a concentration- dependent potentiation of NE-stimulated increase in perfusion pressure suggesting that the Y2 receptor subtype may also be present postjunctionally in this model of the vascular neuroeffector junction. The finding that the profile of this potentiation differed from that elicited by [Leu31Pro34]NPY and, in contrast to the latter, was not attenuated by PYX1, intimates the existence of both distinct subtypes postjunctionally. [Leu31Pro34]NPY also reduced periarterial nerve- stimulated release of NE with a concomitant reduction in perfusion pressure indicating, in addition to the Y2 subtype, the presence of the Y1 receptor prejunctionally in the rat mesenteric arterial bed.
This article has been cited by other articles:
|
|
 |
|
  G. A. Eppel, S. E. Luff, K. M. Denton, and R. G. Evans Type 1 neuropeptide Y receptors and {alpha}1-adrenoceptors in the neural control of regional renal perfusion Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R331 - R340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hoyo, J. C. McGrath, and E. Vila Evidence for Y1-Receptor-Mediated Facilitatory, Modulatory Cotransmission by NPY in the Rat Anococcygeus Muscle J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 38 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
V. Cortés, M.V. Donoso, N. Brown, R. Fanjul, C. López, A. Fournier, and J. P. Huidobro-Toro Synergism between Neuropeptide Y and Norepinephrine Highlights Sympathetic Cotransmission: Studies in Rat Arterial Mesenteric Bed with Neuropeptide Y, Analogs, and BIBP 3226 J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1313 - 1322. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Newhouse and C. E. Hill A role for neuropeptide Y in rat iridial arterioles Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2119 - H2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, D. A. Dimaggio, S. P. Han, and T. C. Westfall Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1737 - H1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Linder, B. M. Lautenschlager, and W. E. Haefeli Subconstrictor Doses of Neuropeptide Y Potentiate {alpha}1-Adrenergic Venoconstriction In Vivo Hypertension, September 1, 1996; 28(3): 483 - 487. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
